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Human leukocyte antigenNon-Hodgkin lymphoma (NHL) is a hematological malignancy of the immune system, and, as with
autoimmune and inﬂammatory diseases (ADs), is inﬂuenced by genetic variation in the major
histocompatibility complex (MHC). Persons with a history of speciﬁc ADs also have increased risk of NHL.
As the coexistence of ADs and NHL could be caused by factors common to both diseases, here we examined
whether some of the associated genetic signals are shared. Overlapping risk loci for NHL subytpes and several
ADs were explored using data from genome-wide association studies. Several common genomic regions and
susceptibility loci were identiﬁed, suggesting a potential shared genetic background. Two independent MHC
regions showed the main overlap, with several alleles in the human leukocyte antigen (HLA) class II region
exhibiting an opposite risk effect for follicular lymphoma and type I diabetes. These results support continued
investigation to further elucidate the relationship between lymphoma and autoimmune diseases.tal Health Sciences, School of
all, Berkeley, CA 94720–7356,
hrisfs@berkeley.edu
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Recent genome-wide association studies (GWAS)1 of the three
most common subtypes of non-Hodgkin lymphoma (NHL) have
detected multiple genetic factors in the major histocompatibility
complex (MHC) region that are associated with follicular lymphoma
(FL) [1,2]. Genetic variation in the MHC, which spans approximately 4
Mb on chromosome 6p21 and encodes N400 known protein-coding
genes (www.ensembl.org, assembly GRCh37), also plays a crucial role
in modulating risk of chronic autoimmune and pro-inﬂammatory
diseases (ADs) such as rheumatoid arthritis (RA), Crohn's disease
(CD) and type 1 diabetes (T1D). Several GWAS have successfully
identiﬁed human leukocyte antigen (HLA) and non-HLA susceptibility
alleles for these diseases (Supplementary Table 1), with some of these
loci shared by more than one AD. Although most of the consistentlyassociated regions have been found in the MHC, genetic variants have
been identiﬁed outside the MHC [3] where some clustering of
susceptibility alleles has been identiﬁed across autoimmune diseases
[4,5].
The co-localization of susceptibility alleles in the MHC for NHL and
ADs suggests the potential for shared risk loci. This hypothesis is
supported by results from several epidemiological studies that have
investigated whether a history of AD inﬂuences NHL risk [6,7]
including a large pooled analysis of 29,423 participants in 12 case–
control studies within the International Lymphoma Epidemiology
Consortium (InterLymph). Increased risks were observed for self-
reported history of Sjögren syndrome with all NHL, marginal zone
lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL) and FL;
systemic lupus erythematosus (SLE) with NHL, DLBCL and MZL; and
celiac disease and psoriasis with T-cell NHL [6]. Interestingly, neither a
history of CD nor T1D was associated with NHL or its subtypes,
whereas results for RAwere heterogeneous among studies. The lack of
consistency for RA may be due to misclassiﬁcation of rheumatoid and
non-rheumatoid arthritis based on self-report. The InterLymph
ﬁndings were relatively consistent with those from a study of
44,350 lymphoid malignancy cases and 122,531 population-based
controls from the U.S. Surveillance Epidemiology and End Results–
Medicare database. Results indicated positive associations between a
history of Sjögren syndrome and risk of DLBCL and MZL, for SLE with
MZL, and for RA with DLBCL [7]. These results suggest that speciﬁc
autoimmune disorders are associated with NHL risk and speciﬁc NHL
subtypes.
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autoimmune diseases and lymphoma subtypes might be due to reverse
causation and thus related to AD severity and related inﬂammatory
processes or to disease treatment [8,9]. To investigatewhether there is a
genetic basis that may contribute to the positive associations observed
betweenNHL risk andhistory of autoimmune disease,we compared our
NHL GWAS data with publicly available genome-wide level data on RA,
CD and T1D from the Wellcome Trust Case-Control Consortium
(WTCCC) [10] to explore potential shared genetic susceptibility
between NHL and these ADs. Our global genomic approach provides a
comprehensive view of the genetic overlap of these diseases that
expands upon previous epidemiologic studies of ADs and NHL risk, and
aims to improve our understanding of mechanisms of lymphomagen-
esis. Analyses focused speciﬁcally on common genetic variants among
the NHL subtypes, FL, chronic lymphocytic leukemia/small lymphocytic
lymphoma (CLL/SLL) andDLBCL, and the autoimmune disorders, RA, CD
and T1D, for which data is publicly available.2. Results
Genome-wide association results for ADs and the major NHL
subtypes, FL, DLBCL and CLL/SLL, are shown in Fig. 1. A strong
association signal can be observed in the MHC region for FL and all the
ADs, especially for T1D and RA. Although several locations across the
genome showed overlapping signals for NHL subtypes and ADs, onlyFig. 1. Genome-wide results for non-Hodgkin lymphoma subtypes (FL, DLBCL, SLL/CLL)
and autoimmune diseases (T1D, RA, CD). Chromosomes are plotted on the x-axis, and
trend p-values (as −log10) adjusted using Genomic Control are plotted on the y-axis.
The T1D, RA and CD panels have been truncated at −log10 (p-value) = 15.two speciﬁc locations showed statistically signiﬁcant overlap (pb0.05,
see Materials and methods). These two 10 kb regions contained
genetic variants that showed association with all ADs and with NHL
subtypes, particularly FL. Due to the high LD structure in the MHC and
because the associated signals could reﬂect LD with a causative
marker located further away, we expanded these two regions to
include neighboring SNPs in linkage disequilibrium (LD, r2N0.6 in
HapMap-CEU).
2.1. Region of overlap on chromosome 6: 31,215–31,671 Mb
The ﬁrst region with overlapping signals for NHL subtypes and ADs
was located in the MHC, from the class I psoriasis susceptibility locus
(PSORS1) where a FL-associated locus (rs6457327, OR=0.59,
p=4.7×10−11) was previously described [1], to the class III region that
overlaps the NHL-associated genes TNF/LTA [11]. Several SNPs were
observed in this region at the pb0.001 level for all the ADs, FL and DLBCL
(Fig. 2), but not for CLL/SLL. Some of these SNPswere associatedwith one
disease only, whereas several loci were associated withmultiple diseases
(Supplementary Table 2). The overlapping loci mainly were found
between FL and the ADs, particularly for T1D and RA. In general, these
common susceptibility alleles were inversely associatedwith disease risk.
Among the shared associated genetic variants, we identiﬁed
several tag SNPs for HLA-B and HLA-C allelotypes (SupplementaryFig. 2. The top panel shows, for each disease, all the genotyped or imputed SNPs that
were ranked in the top-5000 and showed GC-adjusted pb10−4 in the HLA region
between positions 31215 and 31671 Mb. The lower panel shows the same plot after
removing linked SNPs (r2N0.2), with horizontal lines showing the extent of LD for each
SNP (r2N0.6 in each disease). The strongest associated SNP for each disease in the
region is marked with a bigger point.
Table 1
Association analysis of haplotypes tagging HLA alleles.
Allelotype Tag SNPs Tagging
haplotype









HLA-B*0702 rs2596438, rs805288 GC 0.06/0.13 2.0E−4 0.12/0.14 2.0E−4 0.07/0.14 2.30E−29 0.13/0.14 0.0373
HLA-B*4402 rs3130501, rs2769, rs2844533 CTT 0.07/0.07 0.9405 0.14/0.11 6.48E−5 0.09/0.11 0.0098 0.12/0.11 0.0289
HLA-C*0701 rs2524074, rs7382297 CC 0.20/0.16 0.0903 0.18/0.18 0.3025 0.28/0.18 7.58E−34 0.17/0.18 0.292
HLA-DRB1*1301 rs2395173, rs2157051 GG 0.03/0.05 0.0407 0.04/0.07 2.96E−11 0.02/0.06 7.85E−17 0.07/0.07 0.5065
HLA-DQA1*0103 rs2273017, rs2157051 AG 0.04/0.07 0.0221 0.04/0.07 2.47E−13 0.02/0.07 5.70E−26 0.08/0.08 0.9551
HLA-DRB1*0101 rs4947332, rs6457614 GC 0.21/0.13 7.06E−5 0.15/0.11 1.27E−9 0.10/0.11 0.0418 0.12/0.11 0.4453
HLA-DQA*0101 rs6457614, rs1794265 CG 0.21/0.13 7.06E−5 0.16/0.11 1.15E−9 0.10/0.11 0.0418 0.12/0.11 0.4453
The table shows the SNPs and their speciﬁc allele combination (haplotype) that tag each allelotype as described in [12]. The frequency of the tagging haplotype in cases and controls
and the association p-value for the haplotype frequencies in cases vs. control are shown for each disease and were estimated using Haploview [21].
Fig. 3. The top panel shows, for each disease, all the genotyped or imputed SNPs thatwere in
ranked the top-5000 and showed GC-adjusted pb10−4 in the HLA region between positions
32320 and 33112 Mb. The lower panel shows the same plot after removing linked SNPs
(r2N0.2),withhorizontal lines showing theextentof LD for eachSNP(r2N0.6 ineachdisease).
The strongest associated SNP for each disease in the region is marked with a bigger point.
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B*0702 together with rs805288 [12], was inversely associated with FL,
T1D, and RA (ORs=0.52 [0.37–0.74], 0.49 [0.43–0.55] and 0.80 [0.71–
0.89], respectively). Accordingly, the frequency of the rs2596438-
rs805288 haplotype-tagging HLA-B*0702 was higher in controls than
in cases for each of these diseases (Table 1). We also found that
rs9461684, which tags HLA-C*0401 [12], was positively associated
with FL (OR=1.72 [1.27–2.33]) and inversely associated with T1D
(OR=0.58 [0.49–0.69]).
Twoother SNPs in this region, rs3130501 and rs7382297,which are
part of haplotypes tagging, respectively, HLA-B*4402 and HLA-C*0701
[12], were inversely associated with FL and T1D (Supplementary
Table 2). However, the haplotype analysis showed no association of
these haplotypes to FL risk (Table 1), suggesting that linked loci other
than the HLA-B*4402 and HLA-C*0701 allelotypes, might be the
common susceptibility loci.
2.2. Region of overlap on chromosome 6: 32,320–33,112 Mb
Common associations for NHL subtypes and ADs also were found
in HLA class II (Fig. 3). In this region that overlaps the HLA-DR and
HLA-DQ genes, several shared associated loci were found at a pb0.001
level (Supplementary Table 3). Thus, our results showed that SNP
rs2157051, which together with rs2395173 tags HLA-DRB1*1301 [12],
was inversely associated with FL (OR=0.57 [0.41–0.79]) and RA
(OR=0.54 [0.47–0.61]). Haplotype analyses conﬁrmed the inverse
associations of HLA-DRB1*1301 with FL, RA, and T1D (Table 1). Similar
results were found for a second haplotype tagged by the same SNP,
HLA-DQA1*0103, that showed a reduced risk of FL, RA and T1D
(Table 1).
We also observed that SNP rs6457614, which tags the HLA-
DRB1*0101, HLA-DQA1*0101 and HLA-DQB1*0501 allelotypes [12],
was associated with increased risk of FL (OR=1.75 [1.32–2.31]) and
RA (OR=1.45 [1.29–1.64]). Analysis of the haplotypes containing
rs6457614 conﬁrmed the positive association of HLA-DRB1*0101 and
HLA-DQA1*0101 with FL and RA, and interestingly, also showed an
inverse association with T1D (Table 1). Opposing effects on risk
estimates were repeatedly observed for SNPs associated with both FL
and T1D in this region, with FL risk alleles being protective for T1D
(Supplementary Table 3). For example, the rs9469220 A allele was
associated with increased susceptibility to FL (OR=1.47 [1.18–1.85]),
CD (OR=1.23 [1.14–1.35]), and RA (OR=1.17 [1.08–1.27]), and de-
creased risk of T1D (OR=0.37 [0.34–0.41). Similarly, the rs10947332
(A), rs13218331 (C), rs3177928 (A), rs12529093 (G) and rs13209234
(A) alleles were positively associated with FL and RA, and inversely
associated with T1D (Supplementary Table 3).
3. Discussion
Numerous epidemiological studies have shown a link between a
personal history of autoimmune diseases and increased risk of speciﬁclymphoma subtypes. Here, we compared the genetics of the NHL
subtypes, FL, CLL/SLL and DLBCL, with the ADs, RA, T1D and CD using
genome-wide association data to explore the hypothesis of a shared
genetic background between lymphoma and ADs. Our analyses
identiﬁed the presence of common genetic variants between NHL
subtypes and ADs, suggesting a potential shared genetic mechanism.
However, the co-localization of shared genetic variants was observed
more often between FL and ADs than with the other NHL subtypes.
Although several overlapping associated regions were found across
the genome, only two that were located in the HLA class I–III and II
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the HLA region supports the hypothesis that FL and autoimmune
diseases might be inﬂuenced by a common set of immunoregulatory
susceptibility genes.
Among the three ADs studied, CD exhibited the least genetic
overlap with the three NHL subtypes studied. Although CD has been
associated with risk of lymphoma [9], it may be that the association is
more a consequence of disease-related inﬂammatory processes or
related to the immunosuppressive therapies used to treat CD than to
the presence of a shared genetic background.
We found several SNPs common to FL, RA and T1D, which were
mainly located in intergenic or intronic regions. Among these, tag
SNPs for HLA alleles were also identiﬁed, including tags for HLA-
B*0702, HLA-DRB1*1301 and HLA-DQA1*0103, which showed protec-
tion for FL, RA and T1D. Whereas the use of tag SNPs to predict HLA
allelotypes is acceptable for exploratory analyses and hypothesis
generation, these ﬁndings will require validation and follow-up in
HLA allelotype analyses. Further studies that include resequencing to
exploit LD across all variants in the region are warranted to clarify and
identify the causal variants and pathways that are unique and similar
across these diseases.
Of particular interest was the observation that most of the SNPs in
the HLA class II region tended to exert the same effect on disease risk
for FL and RA, but opposite effects for FL and T1D. Speciﬁcally, we
found that the HLA-DRB1*0101/HLA-DQA1*0101 allelotypes showed
increased risk of FL and RA and a reduced risk of T1D. Similarly, other
SNPs not listed as haplotype-tagging SNPs in [12] had contrasting
effects for FL and T1D. It could be that the alleles of these SNPs are
tagging two different undetected allelotypes that are associated
respectively with T1D and FL. It also might be that these alleles
inﬂuence antigen presentation, and are important factors leading to
different antigen-induced immune responses. Associations of oppo-
site alleles to different autoimmune diseases have been observed in
previous studies [13,14] and it has been suggested that risk alleles for
one disease may confer selective advantage for another disease or
resistance to infection. Opposite effects of haplotypes in the HLA class
II region occur both across and within diseases, demonstrating the
complexity of the HLA region. For example, there are several HLA class
II haplotypes that lie within the same region and yet have been shown
to confer increased and decreased risk for FL [15] and T1D [16]. Non-
genetic factors associated with autoimmune disease such as chronic
inﬂammation and treatment effects might also play a role in
lymphomagenesis. Examples include the associations of Helicobacter
pylori infection with gastric MALT lymphoma [17] and hepatitis C
virus infection with B-cell NHL [18]. Further genotyping in additional
cohorts will be necessary to validate these ﬁndings and to further
explore the common genetic backgrounds between these two groups
of diseases and their mechanisms of action.
4. Materials and methods
4.1. Study populations
4.1.1. Non-Hodgkin lymphoma (NHL) cohort
A population-based case–control study of NHL (2055 cases, 2081
controls) that included incident cases diagnosed from 2001 through
2006was conducted in the San Francisco Bay Area. Details of the study
design and methods have been described previously [1]. Brieﬂy,
eligible patients were identiﬁed through the cancer registry and met
the following criteria at diagnosis: aged 20–85 years, resident of one
of the six Bay Area counties and able to complete an in-person
interview in English. Controls were identiﬁed by randomdigit dial and
random sampling of Center for Medicare and Medicaid lists, met the
same eligibility criteria as cases with the exception of NHL diagnosis,
and were frequency-matched to patients by age in 5-year age groups,
sex and county of residence. Blood and/or buccal specimens werecollected from eligible cases and controls who participated in the
laboratory portion of the study (participation rates, 87% and 89%,
respectively). To conﬁrm NHL diagnosis and for consistent classiﬁca-
tion of NHL subtypes using the WHO classiﬁcation, the study's expert
hematopathologist re-reviewed patient diagnostic pathology mate-
rials (including diagnostic slides, pathology, immunohistochemistry
and ﬂow cytometry reports) for N98% of consenting cases, with
review of diagnostic slides in addition to pathology reports conducted
for 54% of cases. Approximately 23% of NHL subtypes were
reclassiﬁed, and approximately 1% of cases were dropped as not
NHL after expert re-review. Eighty-eight percent of FL and 92% of
DLBCL case diagnoses did not change after re-review.
4.1.2. T1D, RA, CD cases and controls datasets
We used genotype data available from the Wellcome Trust Case-
Control Consortium (WTCCC, http://www.wtccc.org.uk/). The WTCCC
study populations used in this study consists of 1963 T1D, 1860 RA,
and 1748 CD cases from Great Britain who mainly self-reported as
white Europeans. A group of 2938 healthy individuals were used as
shared controls for the T1D, RA and CD cases. These WTCCC controls
came from two different sources, 1480 individuals from the 1958
British Birth Cohort and 1458 individuals from an UK national
repository of anonymized DNA samples from 3622 controls (UK
Blood Service sample) recruited as part of the WTCCC project. There
was no evidence of systematic or marked differences in overall allele
frequencies between the two control groups [10]. Phenotype
description for the T1D, RA, CD cohorts and details about the control
study populations have been extensively described elsewhere [10].
4.2. Genotyping and quality control
4.2.1. San Francisco Bay Area NHL study
Details of the genotyping and quality control have been published
previously [2]. Brieﬂy, DNA from 1577 study participants was
genotyped using Illumina HumanCNV370-Duo BeadChip (Illumina,
San Diego, CA), and genotype clustering was conducted with Illumina
Beadstudio software from data ﬁles created by an Illumina BeadArray
reader. Samples with call rates b95% were excluded from further
analysis. SNPs with call ratesb90%, minor allele frequency (MAF)b
0.05 and SNPs on sex chromosomes also were excluded. A total of
312,768 markers genotyped in 1568 individuals (236 FL, 221 CLL/SLL,
291 DLBCL, 9 other NHL and 811 controls) passed these quality control
criteria andwere used for analysis. Genotype data were used to search
for individuals with evidence of non-European ancestry and closely
related individuals, as described below. These individuals were
excluded from further analysis.
4.2.2. T1D, RA, CD and WTCCC control datasets
Samples were genotyped on the Affymetrix GeneChip 500K
Mapping Array Set at the Affymetrix Services Lab in California and
genotypes were called using the CHIAMO algorithm as described
elsewhere [10]. For each dataset, we applied multiple ﬁlters to
exclude individuals and SNPs based on genotype data, using the same
or similar thresholds and procedures as in the WTCCC study [10].
Thus, SNPs were excluded from each study if any of the following
criteria was met: pb5.7×10−7 in test for deviation from Hardy–
Weinberg equilibrium in controls, N5% of data missing for minor allele
frequency (MAF)N0.05 or N1% of data missing for minor allele
frequency (MAF)≤0.05, or allelic p=5.7×10−7 between the two
WTCCC control groups. Individuals withN3% of data missing also were
excluded. A total of 474,016 markers genotyped in 1961 T1D cases,
474,680 markers in 1857 RA cases, 476,476 markers in 1741 CD cases
and 462,424 markers in 2937 controls passed the quality control
criteria and were included in this analysis. In each dataset, genotype
data were used to search for individuals with evidence of non-
European ancestry and closely related individuals, as described below.
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For each dataset (NHL, T1D, RA, CD and WTCCC controls), we
tested population stratiﬁcation using the multidimensional scaling
(MDS) procedure included in the software PLINK v1.04 [19]. To
identify samples of non-European ancestry, we ﬁrst merged the SNPs
that remained after our quality controls with genotypes from 209
unrelated HapMap Phase II individuals from the CEU, YRI and JPT+
CHB panels (JPT individual NA19012 was removed due to low call
rate). In order to avoid strand issues when merging the datasets, we
removed all the ambiguous (A/T and C/G) SNPs. We also removed
non-biallelic SNPs, SNPs with different mapping positions in HapMap
and SNPswithN5%missing data. From the remaining SNPswe selected
a subset of unlinked SNPs by pruning those with r2N0.1 using 50-SNP
windows shifted at 5-SNP intervals. We ran the MDS analysis on the
matrix of genome-wide identity-by-state pairwise distances and
selected 100 as the number of dimensions to be extracted. Each dataset
wasprojected over theﬁrst 2MDSdimensions (which accounted for the
37.8%, 31.10%, 29.9%, 27.8% and 31.9% of the total variance in NHL, T1D,
RA, CD and WTCCC controls, respectively) to identify clusters of
European, Asian and African samples (Supplementary Fig. 1A–E).
The cut-offs used to detect outliers in terms of population
stratiﬁcation were chosen based on inspection of the MDS plots.
Thus, individuals that mapped outside the European cluster (117 in
the NHL cohort [21 FL, 32 DLBCL, 10 SLL/CLL and 54 controls], 21 in
T1D, 27 in RA, 64 in CD and 27 in the WTCCC control datasets),
regardless of their reported origin, were excluded from the
association analysis. The ﬁnal datasets were merged (NHL, T1D, RA,
CD and WTCCC controls) and MDS analysis was conducted as
described above. All the samples formed a single cluster together
with the HapMap-CEU individuals (Supplementary Fig. 1F).
We also used genotype data to search for duplicates and closely
related individuals. For each dataset, we used PLINK 1.04 to obtain
identity-by-descent (IBD) estimates for all pairs of individuals using a
subset of unlinked SNPs. Individuals withN86% IBD sharing (11 in
NHL, 11 in T1D, 66 in RA, 156 in CD and 23 in the WTCCC control
datasets) were excluded. After exclusion of individuals of non-
European ancestry or with evidence of cryptic relatedness, we
estimated an inﬂation factor λ =1.04 in the NHL cohort (λ=1.04,
λ=1.01 and λ=1.04 in FL, DLBCL and CLL/SLL, respectively), and
inﬂation factors λ =1.11, λ =1.10 and λ =1.17 in the combined
datasets of WTCCC controls with T1D, RA and CD, respectively. These




Using the software package BEAGLE 3.0.3[20], we imputed all
known SNPs that were not genotyped or that did no pass direct
genotyping quality controls for each cohort (FL, DLBCL, CLL/SLL, T1D,
RA and CD) separately. Genotypes were imputed based on directly
genotyped SNPs and haplotype information from unrelated CEU
samples in the HapMap Phase II data. When imputing genotypes in
samples of unrelated individuals, BEAGLE produces posterior geno-
type probabilities for imputed genotypes. Those imputed SNPs with
maximum posterior probability lower than 0.9 were set to missing.
Using PLINK v.1.04, we further removed imputed SNPs withN10%
missing data or MAFb0.01. Finally, 1,621,903 SNPs were successfully
imputed in FL, 1,627,752 in DLBCL, 1,624,197 in SLL/CLL, 1,383,155 in
T1D, 1,383,984 in RA and 1,383,575 in CD. Imputed SNPs were tested
in the same way as SNPs directly genotyped as described below.
4.4.2. Single SNP statistical analysis
For each NHL subtype (FL, DLBCL, CLL/SLL) and autoimmune
disease (T1D, RA, CD), association tests were conducted usingdominant and additive models (Cochran–Armitage trend test) as
implemented in PLINK 1.04. ORs and 95% CI were computed for the
dominant model (homozygous or heterozygous versus homozygous
common allele carriers), by median-unbiased estimation using the
mid-p method from the epitools R package (http://sites.google.com/
site/medepi/epitools). Trend p-values in each cohort were adjusted
using the Genomic Control procedure.4.4.3. Search for overlapping signals in ADs and NHL
To look for overlapping regions among ADs and NHL subtypes, we
ﬁrst divided the genome into windows of 10 kb to ﬁne-map
autoimmune-associated regions. We considered a region to be
autoimmune-associated if it contained at least one top 5000 SNP
with an GC-adjusted pb10−4 in all the three ADs studied. We found
19 windows that showed association to all the ADs. Some of these
autoimmune-associated regions showed strong association signals in
NHL subtypes, including two windows located in the HLA class I-III
and II regions that showed FL-associated signals with unadjusted
trend p=3.992×10−5 and 3.593×10−5, respectively. To address the
possibility that the associations of NHL in autoimmune-associated
regions were due to chance, we used a permutation approach to
estimate the likelihood of ﬁnding an NHL signal at these p-value levels
by chance in an autoimmune-associated region. Speciﬁcally, for each
NHL subtype, we randomly permutated the case/control status and
tested association in the 19 autoimmune-associated regions. After
1000 permutations, we found that the probability of ﬁnding an NHL
signal in one of these autoimmune-associated regions with trend p-
values of 3.992×10−5 and 3.593×10−5 is, respectively, p=0.029 and
0.031. This suggests that these two regions are likely to contain real
shared susceptibility loci. Due to the high linkage disequilibrium (LD)
present in the HLA we expanded the associated 10 kb regions to
include neighboringmarkers (up to 500 kb) in LD (r2N0.6 in HapMap-
CEU), allowing the windows to expand up to 456 kb in the HLA class I-
III region, and 792 kb in the HLA class II region.4.4.4. Haplotype analysis
We tested the association of HLA allelotypes by constructing
haplotypes composed of the speciﬁc tag SNP alleles described in [12].
Estimation of haplotype frequencies in cases and controls and
haplotype association tests (chi-square) were performed using
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